Related Experiment Video

Updated: Jul 4, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K

Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis

Christopher P Denton1, Dinesh Khanna2

  • 1Centre for Rheumatology and Connective Tissue Diseases, Division of Medicine, University College London, London NW3 2PF, UK.

The Lancet. Rheumatology
|January 27, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Experiment Videos

Last Updated: Jul 4, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K
A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137

Articles linked to this work by shared authors, journal, and citation graph.

Transcriptomic characterization of transitional B cells reveals four subsets with perturbed activation profiles in scleroderma.

iScience·2026

Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design.

Annals of the rheumatic diseases·2026

Impact of social deprivation on cancer occurrence and cardiovascular events in systemic sclerosis.

Rheumatology advances in practice·2026

Navigating evidence-based recommendations for the management of systemic sclerosis.

Nature reviews. Rheumatology·2026

Understanding patient-reported disease burden in systemic sclerosis: key clinical and demographic features revealed by the EULAR Systemic Sclerosis Impact of Disease (ScleroID) Questionnaire.

EULAR rheumatology open·2026

Circulating biomarkers in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.

Annals of the rheumatic diseases·2026

Relevance of the 2025 ESC guidelines for the diagnosis and management of myocarditis and pericarditis for systemic autoimmune rheumatic diseases.

The Lancet. Rheumatology·2026

Diagnostic accuracy of musculoskeletal ultrasound in suspected polymyalgia rheumatica: a multicentre, cohort study.

The Lancet. Rheumatology·2026

Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.

The Lancet. Rheumatology·2026

Prehabilitation in rheumatology: a missing link in psoriatic disease management.

The Lancet. Rheumatology·2026

Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study.

The Lancet. Rheumatology·2026

Minimal residual disease flow cytometry of peripheral blood B-cell subsets in patients with idiopathic inflammatory myopathies following rituximab therapy: a single-centre, retrospective cohort study.

The Lancet. Rheumatology·2026

PBF/PTTG1IP coordinates focal adhesion formation, polarity and cell motility.

bioRxiv : the preprint server for biology·2026

Dermal bone remodelling by invasive osteoblasts evolved in stem gnathostomes.

bioRxiv : the preprint server for biology·2026

Zilian Ointment Promotes Diabetic Wound Healing via Akt/HIF-1α-Mediated Angiogenesis.

Journal of diabetes research·2026

Sodium tungstate promotes vascularization to support beta cell replacement in diabetes.

EMBO molecular medicine·2026

Divergent SAGA complexes shape the Toxoplasma transcriptome for lytic cycle progression and host interaction.

Nature communications·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us